Back

High glucose enhanced lipoprotein(a) [Lp(a)] oxidation in a manner inhibited by eicosapentaenoic acid (EPA) in vitro

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipids: new pathophysiological and therapeutic insights Lipid Metabolism, Metabolic Syndrome, Diabetes ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Preston Mason

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Rare genetic variants in LDLR, APOB, and PCSK9 are associated with aortic stenosis
Mr S. Jurgens (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Lipidomics-based deep learning algorithms can enhance prediction of obstructive coronary artery disease
Doctor E. Karagiannidis (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Peroxisome proliferator-activated receptor gamma regulates interleukin-6 induced lipoprotein(a) gene expression in human HepG2 cells
Doctor T. Harb (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associated steatohepatitis in mice
Doctor S. Pagano (Geneva, CH)
Abstract Slides Video
Presentation thumbnail
Beyond LDL-cholesterol: effects of alirocumab on the human apolipoproteome
Mr L. Schmidt (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids: new pathophysiological and therapeutic insights

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Genetic variability of lipoprotein(a) controls vascular inflammation/redox signalling and predicts adverse cardiovascular outcomes in coronary artery disease
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels
thumbnail
Congress Presentation
Eicosapentaenoic acid (EPA) modulates inflammasome activation in monocyte-derived macrophages isolated from individuals with and without established atherosclerotic cardiovascular disease (ASCVD).

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources